Is ESALY.PK a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

65 people get ESALY.PK articles and Market Currents by email alert.

Get email alerts on ESALY.PK »

HEADLINES:

Arena Is Still A Great Short
EnhydrisPECorp • Thu, May 23 • 93 Comments
Will Arena's Belviq Be The Next Anti-Obesity Drug To Make The Cover Of Time Magazine?
Reasonable Risk • Thu, May 23 • 23 Comments
The Facebook Effect On Arena's Belviq Sales And Why It Will Ultimately Dwarf Anything Eisai Does
Jacob Smith • Tue, May 21 • 32 Comments
Arena Outlines Belviq Launch And Goals
Spencer Osborne • Fri, May 17 • 34 Comments
Barron's 500: America's Top Companies Leave One Wishing For A Thicker Wallet
Reasonable Risk • Tue, May 7 • 2 Comments
Arena Faces A Convergence Of DEA And European Decisions
Reasonable Risk • Wed, Apr 24 • 103 Comments
As Arena Pharma Begins To Address Mexican Obesity, All Eyes Are Now On The DEA
Heather Ingrassia • Mon, Apr 8 • 27 Comments
AP Pharma's Drug Likely To Receive FDA Approval
Beacon VP Investments • Fri, Mar 22 • 9 Comments
2 Biotech Stocks With Huge Potential For The Speculative Investor
Michael J. Ray • Thu, Mar 14 • 8 Comments
5 Reasons To Stay Bullish On Arena
Chris Lau • Thu, Jan 24 • 18 Comments
Tesaro: Potential Nausea Benefit Or Lack Thereof Key To Valuation
Poonam A. Arora • Tue, Jan 22 • 8 Comments
Get Your Dividend Growth 'Off The Grid': Part 2 - Planet Earth
Five Plus Investor • Tue, Oct 30, 2012 • 100 Comments
Vivus Launches Qsymia - What To Look For Now
Red Acre Investments • Tue, Sep 18, 2012 • 46 Comments
Now That Vivus Was Downgraded, Where Should Investors Turn?
Matt Schilling • Mon, Aug 20, 2012 • 72 Comments
Arena Transfers BELVIQ To Eisai - What It Means
Red Acre Investments • Mon, Jul 30, 2012 • 35 Comments
Biotech Stocks To Consider Going Into Earnings
Jessica King Holden • Wed, Feb 29, 2012 • 3 Comments
Big Pharma's Potential Consumer Growth Avenue
Jessica King Holden • Tue, Feb 7, 2012
Big, Robust Pipelines At Small Biotech Companies
ScriptVolume • Tue, Feb 7, 2012 • 5 Comments
12 Healthcare Companies Expecting Major February Catalysts
Spencer Knight • Wed, Feb 1, 2012 • 8 Comments
Astex Pharmaceuticals Faces FDA Decision On March 6
Markus Aarnio • Thu, Jan 19, 2012 • 4 Comments

To learn more about Seeking Alpha Pro, click here.

Eisai's Rollercoaster: Sepsis Drug Failure Overshadows Eventful Few Days
EP Vantage • Wed, Jan 26, 2011 • 2 Comments
China Biotech Week in Review: Investors Drawn to China Pharma
ChinaBio Today • Sun, Jan 23, 2011
Eisai's Oncology Drug Finally Gets Reviewed
Derek Lowe • Thu, Jun 3, 2010

Arena Is Still A Great Short
EnhydrisPECorp • Thu, May 23 • 93 Comments
Will Arena's Belviq Be The Next Anti-Obesity Drug To Make The Cover Of Time Magazine?
Reasonable Risk • Thu, May 23 • 23 Comments
The Facebook Effect On Arena's Belviq Sales And Why It Will Ultimately Dwarf Anything Eisai Does
Jacob Smith • Tue, May 21 • 32 Comments
Arena Outlines Belviq Launch And Goals
Spencer Osborne • Fri, May 17 • 34 Comments
Barron's 500: America's Top Companies Leave One Wishing For A Thicker Wallet
Reasonable Risk • Tue, May 7 • 2 Comments
Arena Faces A Convergence Of DEA And European Decisions
Reasonable Risk • Wed, Apr 24 • 103 Comments
As Arena Pharma Begins To Address Mexican Obesity, All Eyes Are Now On The DEA
Heather Ingrassia • Mon, Apr 8 • 27 Comments
AP Pharma's Drug Likely To Receive FDA Approval
Beacon VP Investments • Fri, Mar 22 • 9 Comments
2 Biotech Stocks With Huge Potential For The Speculative Investor
Michael J. Ray • Thu, Mar 14 • 8 Comments
5 Reasons To Stay Bullish On Arena
Chris Lau • Thu, Jan 24 • 18 Comments
Tesaro: Potential Nausea Benefit Or Lack Thereof Key To Valuation
Poonam A. Arora • Tue, Jan 22 • 8 Comments
Get Your Dividend Growth 'Off The Grid': Part 2 - Planet Earth
Five Plus Investor • Tue, Oct 30, 2012 • 100 Comments
Vivus Launches Qsymia - What To Look For Now
Red Acre Investments • Tue, Sep 18, 2012 • 46 Comments
Now That Vivus Was Downgraded, Where Should Investors Turn?
Matt Schilling • Mon, Aug 20, 2012 • 72 Comments
Arena Transfers BELVIQ To Eisai - What It Means
Red Acre Investments • Mon, Jul 30, 2012 • 35 Comments
Biotech Stocks To Consider Going Into Earnings
Jessica King Holden • Wed, Feb 29, 2012 • 3 Comments
Big Pharma's Potential Consumer Growth Avenue
Jessica King Holden • Tue, Feb 7, 2012
Big, Robust Pipelines At Small Biotech Companies
ScriptVolume • Tue, Feb 7, 2012 • 5 Comments
12 Healthcare Companies Expecting Major February Catalysts
Spencer Knight • Wed, Feb 1, 2012 • 8 Comments
Astex Pharmaceuticals Faces FDA Decision On March 6
Markus Aarnio • Thu, Jan 19, 2012 • 4 Comments

There are no Transcripts on ESALY.PK.

There are no News articles on ESALY.PK.

ESALY.PK vs. ETF Alternatives

Company Description

Currently, there's no company description for ESALY.PK.

Sector: Healthcare

Industry: Drug Related Products

Country: Japan

All
| Earnings
| Dividends
| M&A
| On the move

Wednesday, April 24, 1:38 PM GE (GE +1.7%) says its healthcare unit GE Healthcare announces a research collaboration agreement with Eisai (ESALY.PK, in which the Japanese pharmacuetical developer will use GEs investigational PET amyloid imaging agent to help select patients for a Phase I clinical Alzhiemers trial. The trial evaluates Eisai's investigational compound E2609, a BACE inhibitor designed to prevent the accumulation of beta amyloid in the brain, which is believed to play a role in the in the development of the disease. 1 Comment [Healthcare, On the Move]
Wednesday, April 3, 11:51 AM Astex Pharmaceuticals (ASTX +12.5%) gets a pop from RBC today, who initiated coverage with an Outperform and a $9 price target, calling it an "undiscovered gem." The firm says the ASTX could have a blockbuster in its pipeline with its experimental blood cancer drug, SGI-110, which is thought to be a safer and more effective version of an already approved therapy it licenses to Eisai (ESALY.PK) and JNJ. ASTX owns all the rights to SGI-110, giving it big upside potential if it gets approved. Additionally, the company reported earlier that it plans to present "significant data" at the AACR annual meeting on Saturday. Comment! [Healthcare, On the Move]
Monday, March 4, 8:15 AM More on Arena Pharmaceutical (ARNA -1.7%) Q4: In addition to revenues from Belviq sales, Arena expects $66.5M in milestone payments from marketing and distribution partner Eisai in 2013, $6M from amortization of upfront payments, and $3M from manufacturing services from Siegfried. Arena also expects R&D costs of $70-78M and G&A expenses of $28-34M. (PR) Comment! [Healthcare, Earnings]
Monday, December 24, 2012, 7:27 AM The marketing partner (Eisai ESALY.PK) for Arena's (ARNA) obesity-fighting Belviq has petitioned the DEA to expedite its approval process. If granted (this sort of request is rarely denied), this could have the drug in pharmacies on February 7, writes Joe Dedvukaj. Combined with what looks to be imminent EU approval, Street analysts will find themselves needing to catch up to lofty sales figures. 3 Comments [Healthcare, Quick Ideas]
Monday, October 22, 2012, 7:53 PM The FDA approves Japanese drug developer Eisai's (ESALY.PK) Fycompa tablets for the treatment of partial onset seizures in epilepsy patients. Partial seizures are the most common type seen in people with epilepsy. Comment! [Healthcare, Global & FX]
Monday, July 30, 2012, 11:43 AM Arena (ARNA) transfers the marketing rights for its Belviq diet drug to partner Eisai (ESALY.PK), which will market the pill in the U.S. and apply for authorization in other countries in the Americas. SA author Red Acre Investments notes that what is not explicitly stated is that Eisai, not Arena, will run all of the pediatric and cardiovascular outcome trials that are required under Belviq's FDA approval letter (.pdf). (PR) 1 Comment [Healthcare]
Thursday, February 9, 2012, 1:54 PM A FDA panel rejects Eisai's (ESALY.PK) blood drug Dacogen for use as a treatment for leukemia after finding that a study "failed to demonstrate benefit on statistical interpretation." Shares of Dacogen-seller Astex Pharmaceuticals (ASTX) - currently halted - could feel a jolt off the news when trading resumes. Comment! [Healthcare]
Wednesday, February 8, 2012, 1:10 PM The FDA issues a warning on stomach-acid medications that can increase the risk of a dangerous bacterial infection. Numerours drugs include the at-risk PPI medication with Protonix, AcipHex, and Nexium being some of the larger names. Big pharma players that produce PPIs include JNJ, MRK, PFE, AZN, and ESALY.PK. Comment! [Healthcare, U.S. Economy]
Tuesday, January 3, 2012, 4:13 PM Arena Pharmaceuticals (ARNA), along with its partner Eisai (ESALY.PK), says it's submitted its response to the Complete Response Letter issued by the FDA, following its review of the lorcaserin New Drug Application. ARNA +1.6% AH. Comment! [Global & FX, Healthcare]

ESALY.PK Eisai Co Ltd Spons A

ESALY.PK

Eisai Co Ltd Spons A